176 related articles for article (PubMed ID: 30059438)
1. Statewide Success of Staged Sacral Neuromodulation for the Treatment of Urinary Complaints in California (2005-2011).
Dobberfuhl AD; Mahal A; Dallas KB; Choi KM; Comiter CV; Elliott CS
Female Pelvic Med Reconstr Surg; 2020 Jul; 26(7):437-442. PubMed ID: 30059438
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
[TBL] [Abstract][Full Text] [Related]
3. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
4. Onset of Action of Sacral Neuromodulation in Lower Urinary Tract Dysfunction-What is the Optimal Duration of Test Stimulation?
Jairam R; Drossaerts J; Marcelissen T; van Koeveringe G; van Kerrebroeck P
J Urol; 2018 Jun; 199(6):1584-1590. PubMed ID: 29291416
[TBL] [Abstract][Full Text] [Related]
5. Risk factors for explantation due to infection after sacral neuromodulation: a multicenter retrospective case-control study.
Myer ENB; Petrikovets A; Slocum PD; Lee TG; Carter-Brooks CM; Noor N; Carlos DM; Wu E; Van Eck K; Fashokun TB; Yurteri-Kaplan L; Chen CCG
Am J Obstet Gynecol; 2018 Jul; 219(1):78.e1-78.e9. PubMed ID: 29630890
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
[TBL] [Abstract][Full Text] [Related]
7. A Supervised 3 Weeks Test Phase in Sacral Neuromodulation with a 1-Year Followup.
Tilborghs S; Van de Borne S; Vaganée D; De Win G; De Wachter S
J Urol; 2021 Jan; 205(1):206-212. PubMed ID: 32716692
[TBL] [Abstract][Full Text] [Related]
8. Neuromodulation in urology, state of the art.
Ammirati E; Giammò A; Manassero A; Carone R
Urologia; 2019 Nov; 86(4):177-182. PubMed ID: 31368415
[TBL] [Abstract][Full Text] [Related]
9. Is sensory testing during lead placement crucial for achieving positive outcomes after sacral neuromodulation?
Peters KM; Killinger KA; Boura JA
Neurourol Urodyn; 2011 Nov; 30(8):1489-92. PubMed ID: 21674596
[TBL] [Abstract][Full Text] [Related]
10. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience.
Sutherland SE; Lavers A; Carlson A; Holtz C; Kesha J; Siegel SW
Neurourol Urodyn; 2007; 26(1):19-28; discussion 36. PubMed ID: 17078071
[TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation for refractory overactive bladder, interstitial cystitis, and painful bladder syndrome.
Laviana A; Jellison F; Kim JH
Neurosurg Clin N Am; 2014 Jan; 25(1):33-46. PubMed ID: 24262898
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation using the standardized tined lead implantation technique with a curved vs a straight stylet: 2-year clinical outcomes and sensory responses to lead stimulation.
Vaganée D; Kessler TM; Van de Borne S; De Win G; De Wachter S
BJU Int; 2019 May; 123(5A):E7-E13. PubMed ID: 30537223
[TBL] [Abstract][Full Text] [Related]
13. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
[TBL] [Abstract][Full Text] [Related]
14. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.
Peeters K; Sahai A; De Ridder D; Van Der Aa F
BJU Int; 2014 May; 113(5):789-94. PubMed ID: 24238278
[TBL] [Abstract][Full Text] [Related]
16. Sacral neuromodulation for overactive bladder in women: do age and comorbidities make a difference?
High RA; Winkelman W; Panza J; Sanderson DJ; Yuen H; Halder G; Shaver C; Bird ET; Rogers RG; Danford JM
Int Urogynecol J; 2021 Jan; 32(1):149-157. PubMed ID: 32588075
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
[TBL] [Abstract][Full Text] [Related]
18. Long term safety of sacral nerve modulation in medicare beneficiaries.
Chughtai B; Sedrakyan A; Isaacs A; Lee R; Te A; Kaplan S
Neurourol Urodyn; 2015 Sep; 34(7):659-63. PubMed ID: 25066920
[TBL] [Abstract][Full Text] [Related]
19. Physician Use of Sacral Neuromodulation Among Medicare Beneficiaries With Overactive Bladder and Urinary Retention.
Suskind AM; Clemens JQ; Zhang Y; Hollenbeck BK
Urology; 2015 Jul; 86(1):30-4. PubMed ID: 26026856
[TBL] [Abstract][Full Text] [Related]
20. Comparison of patients undergoing a two-stage sacral nerve stimulation procedure: is there a cost benefit for a single-stage procedure?
Nikolavsky D; Killinger K; Boura J; Peters K
Int Urol Nephrol; 2011 Dec; 43(4):997-1002. PubMed ID: 21547470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
